These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 17495280)

  • 21. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.
    Christopher R; Covington P; Davenport M; Fleck P; Mekki QA; Wann ER; Karim A
    Clin Ther; 2008 Mar; 30(3):513-27. PubMed ID: 18405789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes.
    Skrumsager BK; Nielsen KK; Müller M; Pabst G; Drake PG; Edsberg B
    J Clin Pharmacol; 2003 Nov; 43(11):1244-56. PubMed ID: 14551179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics, safety, and tolerability of intramuscular ziprasidone in healthy volunteers.
    Miceli JJ; Wilner KD; Swan SK; Tensfeldt TG
    J Clin Pharmacol; 2005 Jun; 45(6):620-30. PubMed ID: 15901743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single- and multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy Japanese adult smokers.
    Kikkawa H; Maruyama N; Fujimoto Y; Hasunuma T
    J Clin Pharmacol; 2011 Apr; 51(4):527-37. PubMed ID: 20551220
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
    Zhao RK; Cheng G; Tang J; Song J; Peng WX
    Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
    Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P
    Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and CNS pharmacodynamics of the 5-HT1A agonist buspirone in humans following acute L-tryptophan depletion challenge.
    Jagannathan V; Venitz J
    Methods Find Exp Clin Pharmacol; 1997 Jun; 19(5):351-62. PubMed ID: 9379784
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ghrelin agonist (TZP-101): safety, pharmacokinetics and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study.
    Lasseter KC; Shaughnessy L; Cummings D; Pezzullo JC; Wargin W; Gagnon R; Oliva J; Kosutic G
    J Clin Pharmacol; 2008 Feb; 48(2):193-202. PubMed ID: 18199894
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Two single-center, double-blind, randomized, placebo-controlled, phase I studies to investigate the tolerability and pharmacokinetics of CH-1504, an antifolate, in healthy male subjects.
    Mant T; Jurcevic S; Szakacs C; Adams L; Boland J; Hewitt LA
    Clin Ther; 2008 Jan; 30(1):131-42. PubMed ID: 18343249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and pharmacodynamics of AR9281, an inhibitor of soluble epoxide hydrolase, in single- and multiple-dose studies in healthy human subjects.
    Chen D; Whitcomb R; MacIntyre E; Tran V; Do ZN; Sabry J; Patel DV; Anandan SK; Gless R; Webb HK
    J Clin Pharmacol; 2012 Mar; 52(3):319-28. PubMed ID: 21422238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.
    Herman GA; Stevens C; Van Dyck K; Bergman A; Yi B; De Smet M; Snyder K; Hilliard D; Tanen M; Tanaka W; Wang AQ; Zeng W; Musson D; Winchell G; Davies MJ; Ramael S; Gottesdiener KM; Wagner JA
    Clin Pharmacol Ther; 2005 Dec; 78(6):675-88. PubMed ID: 16338283
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.
    Abbas R; Hug BA; Leister C; Gaaloul ME; Chalon S; Sonnichsen D
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):221-7. PubMed ID: 21691746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a multiple-dose study in healthy humans.
    Matsushima N; Jakubowski JA; Asai F; Naganuma H; Brandt JT; Hirota T; Freestone S; Winters KJ
    Platelets; 2006 Jun; 17(4):218-26. PubMed ID: 16769599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers.
    Addy C; Li S; Agrawal N; Stone J; Majumdar A; Zhong L; Li H; Yuan J; Maes A; Rothenberg P; Cote J; Rosko K; Cummings C; Warrington S; Boyce M; Gottesdiener K; Stoch A; Wagner J
    J Clin Pharmacol; 2008 Apr; 48(4):418-27. PubMed ID: 18258750
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects.
    Weber C; Schmitt R; Birnboeck H; Hopfgartner G; van Marle SP; Peeters PA; Jonkman JH; Jones CR
    Clin Pharmacol Ther; 1996 Aug; 60(2):124-37. PubMed ID: 8823230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tolerability, pharmacokinetics, and neuroendocrine effects of PRX-00023, a novel 5-HT1A agonist, in healthy subjects.
    Iyer GR; Reinhard JF; Oshana S; Kauffman M; Donahue S
    J Clin Pharmacol; 2007 Jul; 47(7):817-24. PubMed ID: 17495280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: a 28-day, open-label study.
    Mathew SJ; Garakani A; Reinhard JF; Oshana S; Donahue S
    Clin Ther; 2008 Sep; 30(9):1658-66. PubMed ID: 18840371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.
    Becker OM; Dhanoa DS; Marantz Y; Chen D; Shacham S; Cheruku S; Heifetz A; Mohanty P; Fichman M; Sharadendu A; Nudelman R; Kauffman M; Noiman S
    J Med Chem; 2006 Jun; 49(11):3116-35. PubMed ID: 16722631
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial.
    Rickels K; Mathew S; Banov MD; Zimbroff DL; Oshana S; Parsons EC; Donahue SR; Kauffman M; Iyer GR; Reinhard JF
    J Clin Psychopharmacol; 2008 Apr; 28(2):235-9. PubMed ID: 18344738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.